REVBW

distress 6/10 · elevated risk

$0.01-7%today-15% from 52w high

revbiosciences.com8 employeesFounded 2019San Diego, CA

Lead: chronic kidney disease

Revenue

pre-revenue

Liquidity

$14M

Runway

1.6 yrs

Shares 1y

+130%

Price & events

-7.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

-6.6%

-3.4%

-6.6%

—

-7.6%

All

Overview

Market Cap: $33.22K
Volume: 29.78K
52 Week Range: $0.01 – $0.01
Total Shares: 3.91M
Float Shares: 3.44M
RVOL: 8.99x
Beta: -0.12

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 5

Wednesday, September 10th at 8:30 am Eastern Timeconferencedata presentationsecondaryGemini · Data discussion webcast/conference call to review top-line PRIME study results.SEC 8-K
this monthenrollment completesecondaryPhase 1Gemini · Enrollment completion of PRIME Phase 1b study in CKD patients expected in July 2025.SEC 8-K
mid 2025readoutPhase 1Gemini · Top-line safety, tolerability, and cellular protection data from PRIME Phase 1b studySEC 8-K
early 2025trial initiationsecondaryPhase 1Gemini · Plan to initiate Phase 1b study of Gemini as preconditioning treatment in CKD patientsSEC 8-K
late 2024trial initiationsecondaryPhase 1Gemini · Phase 1b study initiation for Gemini in AKISEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 3,908,420 · 2 offerings/1y · 2 PIPEs

2026-07-138-Kmaterial_agreement
2026-02-11EFFECTshelf_effective
2026-02-11424B3offering
2026-01-30S-3shelf_registration
2026-01-298-Kprivate_placement
2025-09-30S-3/Ashelf_registration
2025-09-30424B3offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — chronic kidney disease

LLYELI LILLY & Co$1094.4B · D3
IRONDisc Medicine, Inc.$2.8B · D1
MLYSMineralys Therapeutics, Inc.$2.1B · D6
AKBAAkebia Therapeutics, Inc.$329M · D0
UNCYUnicycive Therapeutics, Inc.$147M · D6
REVBREVELATION BIOSCIENCES, INC.$4M · D5
BAYRY— · D2
AZNASTRAZENECA PLC— · D3
NONOFNOVO NORDISK A S— · D2
PROKPROKIDNEY CORP.— · D5